louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02722564: Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Intoxication
Lead sponsor: St. Luke's Hospital and Health Network, Pennsylvania
Sponsor class: OTHER
First posted: 2016-03-30
Enrollment: 55
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This will be a prospective survey study. The participants will all be volunteers of legal drinking age. Each participant will consume one alcoholic beverage (beer) at a time and then will be asked to verbally estimate their current blood alcohol concentration and if the subject feels they are able to drive. At that time, their BAC level will be measured objectively using a breath alcohol test (BAT) device. The participant will not be told their objective value. This will continue with a verbal estimate and actual BAT reading after every drink until the participant reaches a minimum BAC of 0.10. At this time, participants will continue to be monitored until their BAC falls to 0.08 and they are clinically sober. As their blood alcohol level decreases, the investigators will ask the participant to estimate their level every hour along with an actual reading until reaching 0.08. Statistical analyses will be used to determine how accurate self estimation is in regards to blood alcohol content.


Eligibility criteria: Inclusion Criteria:

* over the legal age (21years old) to drink alcohol.

Exclusion Criteria:

* Volunteers will be excluded from the study if they suffer from any of the following conditions:

Alcoholism, Diabetes, Kidney/bladder stones, Kidney disease, Liver disease, Stomach ulcer, Organ transplant patients, Dialysis patients, and patients with alcohol allergies.

Primary outcomes:
measure: Change in Breath Alcohol Content Between the Estimated Level and the Actual Level as Measured by an Alco Sensor IV Device
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Bethlehem
country: United States
facility: St. Luke's University Hospital
state: Pennsylvania
Study officials:
References:
citation: Kraus CL, Salazar NC, Mitchell JR, Florin WD, Guenther B, Brady D, Swartzwelder SH, White AM. Inconsistencies between actual and estimated blood alcohol concentrations in a field study of college students: do students really know how much they drink? Alcohol Clin Exp Res. 2005 Sep;29(9):1672-6. doi: 10.1097/01.alc.0000179205.24180.4a.
Clinical trial NCT02449564: The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Solid Tumor
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2015-05-20
Enrollment: 5
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a single-arm, phase II study of sirolimus in patient with PIK3CA mutation and PIK3CA amplication Refractory solid tumors.

sirolimus 1mg will be administered orally qd daily.

To investigate the efficacy of sirolimus in patients with PIK3CA mutation and PIK3CA amplication Refractory solid tumors.


Eligibility criteria: Inclusion Criteria:

1. Provision of fully informed consent prior to any study specific procedures.
2. Patients must be ≥20 years of age.
3. PIK3CA amplification and/or PIK3CA mutation Refractory Solid Tumors.
4. ECOG performance status 0-2.
5. Have measurable or evaluated disease based on RECIST1.1. as determined by investigator.
6. Adequate Organ Function Laboratory Values

   * Absolute neutrophil count ≥ 1.5 x 109/L, Hemoglobin ≥ 9g/dL, Platelets ≥ 100 x 109/L
   * bilirubin ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal (5.0 X upper limit of normal , for subjects with liver metastases)
   * creatinine ≤1.5 x UNL
7. Patients of child-bearing potential should be using adequate contraceptive measures (two forms of highly reliable methods) should not be breast feeding and must have a negative pregnancy test prior to start of dosing.
8. Adequate heart function.

Exclusion Criteria:

1. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
2. Has known active central nervous system (CNS) metastases.
3. Has an active infection requiring systemic therapy.
4. Pregnancy or breast feeding
5. Patients with cardiac problem.

Primary outcomes:
measure: progression-free survival
timeFrame: 24 weeks
Secondary outcomes:
measure: overall response rate
timeFrame: 24 weeks
measure: overall survival
timeFrame: 24 weeks
measure: Time to progressive
timeFrame: 24 weeks
measure: Number of subjects with Adverse Events as a measure of toxicity profile
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical center
Study officials:
affiliation: Samsung Medical Center,Seoul,Korea
name: Jee yun Lee, MD,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00751764: Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
Official title: An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Infection
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2008-09-12
Enrollment: 12
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.


Eligibility criteria: Inclusion criteria:

Healthy lactating women aged 21 to 45 years inclusive at screening. Women should:

* Be at least 12-weeks postpartum after uncomplicated delivery with a full milk supply established.
* Be willing to discontinue breastfeeding permanently and should be in the process of weaning their infant. Care should be taken to ensure that subjects have not discontinued breastfeeding an infant in order to participate in the study.
* Not plan to breastfeed within 9 months of study drug administration.
* Be willing to fully express breast milk from both breasts during the duration of the milk collection portion of the study. Subjects must be able to express milk from each breast at each pumping session using a breast pump.
* Body mass index in the range of 18 to 35 kg/m2.

Exclusion criteria:

* Presence or history of any disorder that may prevent the successful completion of the study.
* Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

Primary outcomes:
measure: Blood samples
timeFrame: 4 months
Secondary outcomes:
measure: Safety based on adverse event monitoring, vital sign measurements, 12-lead ECGs and routine lab tests.
timeFrame: 4 months
Other outcomes:
Locations:
city: Plymouth
country: United Kingdom
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03226964: Assessment of High Flow Nasal Cannula Oxygenation in EBUS Bronchoscopy
Official title: Assessment of High Flow Nasal Cannula Oxygenation in EBUS Bronchoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Cancer
Lymphadenopathy
Keywords: endobronchial ultrasound
high flow nasal oxygen
Lead sponsor: University College Hospital Galway
Sponsor class: OTHER
First posted: 2017-07-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective randomised trial where a computer will randomly allocate

patients to one of two possible methods of delivering oxygen during the procedure of

bronchoscopy. This trial compares high flow nasal cannula (HFNC) with nasal prongs in

delivering oxygen to patients undergoing endo-bronchial ultrasound guided trans-

bronchial nodal aspiration (EBUS-TBNA) a specialised form of bronchoscopy procedure.

HFNC uses humidified higher gas flow rates than conventional low flow systems such as

nasal prongs which are limited by the respiratory rate and effort.


Eligibility criteria: Inclusion Criteria:

* Subjects with a peripheral arterial pulse oximetry ≥ 90% breathing room air
* Age ≥ 18 years
* Able to breathe spontaneously throughout the procedure

Exclusion Criteria:

* Respiratory or cardiac failure
* Recent myocardial infarction \< 6 weeks ago
* On long term oxygen therapy, those with tracheostomy and/ or non-invasive or invasive mechanical ventilation
* Nasal and/ or nasopharyngeal disease
* Inability to give informed consent
* Dementia
* Hepatic or end stage renal disease
* Pregnancy

Primary outcomes:
measure: drop in oxygen saturation during procedure
timeFrame: through procedure completion defined as withdrawing scope from patient's mouth, an average of 30 minutes
Secondary outcomes:
measure: change in venous CO2
timeFrame: 1 hour after procedure
measure: end tidal CO2 during procedure
timeFrame: through procedure completion defined as withdrawing scope from patient's mouth an average of 30 minutes
measure: Patient experience measure on a visual analogue scale
timeFrame: up to 3 hours after procedure
measure: endotracheal intubation during or post procedure
timeFrame: 24 hours
Other outcomes:
Locations:
city: Galway
country: Ireland
facility: University Hospital Galway
Study officials:
affiliation: University Hospital Galway
name: David Breen
role: STUDY_CHAIR
References:
Clinical trial NCT03298464: Study of NGM313 in Obese Participants
Official title: A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obese
Lead sponsor: NGM Biopharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2017-10-02
Enrollment: 25
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants


Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) of 30-43 kg/m2
* Waist circumference \> 40 inches in males or \> 30 inches in females
* Normal ECG readings

Exclusion Criteria:

* Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
* History of any known Congestive heart failure (CHF)
* History of macrovascular disease

Primary outcomes:
measure: Evaluation of whole body insulin sensitivity measured as insulin sensitivity index (M and Si) following intravenous insulin administration
timeFrame: 28 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Prosciento
state: California
Study officials:
References:
Clinical trial NCT04989764: COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER
Official title: COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy
Lead sponsor: Shaukat Khanum Memorial Cancer Hospital & Research Centre
Sponsor class: OTHER
First posted: 2021-08-04
Enrollment: 108
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer patients who had histologically proven gastric adenocarcinoma diagnosed at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH \& RC), between January 2015 and December 2019

Brief summary: * Patients with gastric adenocarcinoma
* Comparison: perioperative chemotherapy vs. adjuvant therapy.
* Sample size differences between the two groups.
* Kaplan meier survival analysis, overall survival and disease free survival


Eligibility criteria: Inclusion Criteria:

* We included histologically proven gastric adenocarcinoma patient with operable disease and the patients who completed their prescribed perioperative or adjuvant chemotherapy cycles

Exclusion Criteria:

* Patients were excluded if they had Tis or T1, N0 disease, inoperable disease, metastatic. In addition, all those who did not undergo adequate lymphadenectomy (\< D2) or had R1 margins following surgery were excluded

Primary outcomes:
measure: The overall survival
timeFrame: from January 2015 till December 2019
measure: The disease-free survival
timeFrame: from January 2015 till December 2019
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06677164: Gluteus Maximus Strengthening Exercises Augmented by High-Intensity Laser Therapy in Patients With Plantar Fasciopathy
Official title: Gluteus Maximus Strengthening Exercises Augmented by High-Intensity Laser Therapy in Patients With Chronic Plantar Fasciopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Plantar Fascia
Keywords: Plantar heel pain
obese
laser therapy
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2024-11-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Plantar heel pain is one of the most commonly encountered problems of the feet in adults \[1\]. It accounts for nearly 11%-15% of all foot symptoms, The purpose of this study was to investigate the effectiveness of high intensity laser therapy combined with gluteus Maximus strengthening exercise on pain, thickness of plantar fascia, and function of the foot.


Eligibility criteria: Inclusion Criteria:

* Unilateral plantar heel pain with or without calcaneal spur for more than 3 months.
* Tenderness at the insertion of the plantar fascia
* BMI index will be from 25 up to 30
* Patient will wear silicone insole .
* Diagnosis of PF based on orthopedic referral

Exclusion Criteria:

* Patients with presence of foot deformity,
* systemic inflammatory arthritis disease,
* foot surgery, or
* plantar heel pain due to trauma,
* wound, or infection in the foot,
* received oral corticosteroids

Primary outcomes:
measure: Pain assessment
timeFrame: 3 months
measure: Plantar fascia thickness
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Deraya university
Study officials:
References:
Clinical trial NCT01153464: Effectiveness of Extended Treatment for Drug Dependence (ETDD) in the City Study
Official title: Effectiveness of Extended Treatment for Drug Dependence - City Supplement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine Dependence
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2010-06-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This protocol (a supplement to 805466) is to test whether our telephone continuing care model can be implemented successfully by "real world" publicly funded programs. Participants will be recruited from Philadelphia's Department of Behavioral Health - run drug programs. The investigators will train city telephone care managers to deliver our telephone continuing care intervention to patients in this program. The investigators will randomize 200 to receive this intervention or usual care and follow them for 12 months.


Eligibility criteria: Inclusion Criteria:

* (1) qualify for a DSM-IV diagnosis of cocaine dependence, with cocaine use in the 6 months prior to entrance into the City of Philadelphia Department of Behavioral Health facilities or controlled environment;
* (2) 18 to 75 years of age;
* (3) no current psychotic disorder (as assessed with the psychotic screen from the SCID) or evidence of dementia severe enough to prevent participation in outpatient treatment;
* (4) no acute medical problem requiring immediate inpatient treatment;
* (5) no current participation in methadone or other modes of Drug and Alcohol treatment, other than an Intensive Outpatient Program;
* (6) willingness to be randomized and participate in research.
* (7) Finally, because of study follow-up requirements, subjects will be able to provide the name, verified telephone number, and address of at least two contacts who can provide locating information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.

Exclusion Criteria:

* Current dependence on opiates is an exclusion as those participants may be better served as part of a methadone program rather than a telephone based therapy protocol. Also, if patients are court-ordered to treatment, or otherwise considered prisoners, they will not be included in the study.

Primary outcomes:
measure: Time Line Follow Back
timeFrame: 3 month
measure: Time Line Follow Back
timeFrame: 6 month
measure: Time Line Follow Back
timeFrame: 9 month
measure: Time Line Follow Back
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT04500964: Transcatheter Aortic Valve Replacement for Failed Transcatheter Aortic Valve
Official title: Transcatheter Aortic Valve Replacement for Failed Transcatheter Aortic Valve. An International Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Failed Transcather Aortic Valve
Lead sponsor: IRCCS Policlinico S. Donato
Sponsor class: OTHER
First posted: 2020-08-06
Enrollment: 173
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with failed transcather aortic valve

Brief summary: Patients with failed transcather aortic valve (stenotic, regurgitant, both) and indication to further transcatheter aortic valve replacement (TAVR).

The purpouse of this study is to evaluate the indication to a second TAVR, the selection criteria of the second transcatheter aortic valve, procedural and clinical outcomes.

The primary endpoint of the study is overall mortality and Cardiovascular mortality at 1 year


Eligibility criteria: Inclusion Criteria:

* Patients with failed transcather aortic valve (stenotic, regurgitant, both) and indication to further transcatheter aortic valve replacement (TAVR).

Exclusion Criteria:

-

Primary outcomes:
measure: Overall mortality
timeFrame: 1 year
Secondary outcomes:
measure: VARC-3 Events
timeFrame: 1 year
Other outcomes:
Locations:
city: San Donato Milanese
country: Italy
facility: IRCCS Policlinico San Donato
state: Milan
Study officials:
References:
citation: Testa L, Casenghi M, Criscione E, Van Mieghem NM, Tchetche D, Asgar AW, De Backer O, Latib A, Reimers B, Stefanini G, Trani C, Giannini F, Bartorelli A, Wojakowski W, Dabrowski M, Jagielak D, Banning AP, Kharbanda R, Moreno R, Schofer J, Brinkmann C, van Royen N, Pinto D, Serra A, Segev A, Giordano A, Brambilla N, Agnifili M, Rubbio AP, Squillace M, Oreglia J, Tanja R, McCabe JM, Abizaid A, Voskuil M, Teles R, Zoccai GB, Sondergaard L, Bedogni F. Prosthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT-PPM international project. Front Cardiovasc Med. 2022 Jul 29;9:931207. doi: 10.3389/fcvm.2022.931207. eCollection 2022.
citation: Testa L, Agnifili M, Van Mieghem NM, Tchetche D, Asgar AW, De Backer O, Latib A, Reimers B, Stefanini G, Trani C, Colombo A, Giannini F, Bartorelli A, Wojakowski W, Dabrowski M, Jagielak D, Banning AP, Kharbanda R, Moreno R, Schofer J, van Royen N, Pinto D, Serra A, Segev A, Giordano A, Brambilla N, Popolo Rubbio A, Casenghi M, Oreglia J, De Marco F, Tanja R, McCabe JM, Abizaid A, Voskuil M, Teles R, Biondi Zoccai G, Bianchi G, Sondergaard L, Bedogni F. Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project. Circ Cardiovasc Interv. 2021 Jun;14(6):e010440. doi: 10.1161/CIRCINTERVENTIONS.120.010440. Epub 2021 Jun 7.
Clinical trial NCT01747564: A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects
Official title: A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Subjects
Plasma Concentration of Mirabegron
Keywords: Pharmacokinetics
Mirabegron
Phase 1
YM178
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2012-12-11
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to evaluate safety and absorption, distribution and elimination of mirabegron after oral administration to Chinese subjects.

Detailed description: This study is an open-label study. The subjects will receive single administration of mirabegron in a fasted condition. After the non-dosing period, subjects will receive mirabegron for 8 days.

Eligibility criteria: Inclusion Criteria:

* Body weight: (male) over 50.0kg and less than 80.0kg (female) over 40.0kg and less than 70.0kg
* Body Mass Index: over 17.6 and less than 26.4 kg/m
* Chinese subjects
* Healthy judged by investigator or sub-investigator

Exclusion Criteria:

* Received any investigational drugs within 120 days before the screening assessment
* Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment
* Received medication within 7 days before hospital admission
* A deviation from the assessment criteria of physical examinations or laboratory tests at screening or upon admission
* History of drug allergies
* With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases
* Received mirabegron beforehand
* Glaucoma patient

Primary outcomes:
measure: Pharmacokinetic (PK) profile for ASP015K (in plasma): Cmax, AUClast, AUCinf and AUC0-24h
timeFrame: Day 1-5 and Day 10, 11, 14-21
Secondary outcomes:
measure: Safety assessed by the incidence of adverse events, vital signs, lab-test and 12-lead ECGs
timeFrame: Through day 25
Other outcomes:
Locations:
city: Kyushu
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Medical Director
role: STUDY_DIRECTOR
References: